Key result
First-trimester maternal CMV seroprevalence was 23.4%, with seropositivity significantly higher among women born outside Canada and the USA compared to those born in Canada or the USA (OR 2.8).
Why the study?
Maternal CMV infection in the first trimester of pregnancy is a public health concern that increases the risk of severe neurodevelopmental outcomes compared to later infections.
Cohort (n=4,111)
No
Odds Ratio: 2.8 (95% CI 1.5–4.9)
Absolute Event Rate: 65.9% vs 21.7%
p-value: p=<0.001
Maternal CMV seroprevalence and primary infection rates during pregnancy in Quebec are relatively low, with parity, ethnicity, and country of birth identified as key risk factors for seropositivity.
May inform targeted CMV risk assessment in immigrant pregnancies; leaves open need for outcome studies before screening changes.
INTRODUCTION: Maternal Cytomegalovirus (CMV) infection in the first trimester (T1) of pregnancy is a public health concern, as it increases the risk of severe neurodevelopmental outcomes associated with congenital infection compared to infections occurring later during pregnancy. OBJECTIVES: To determine CMV seroprevalence in T1 of pregnancy, its trend, risk factors and the incidence rate of primary infection during pregnancy. METHODS: Using the biobank of the prospective cohort "Grossesse en Santé de Québec" collected between April 2005 and March 2010 at the Québec-Laval Hospital, Québec, Canada, maternal CMV serology was determined using Abbott Architect Chemiluminescence microparticle immunoassays for immunoglobulin G(IgG), immunoglobulin M(IgM) titration and IgG avidity testing. Changepoint detection analysis was used to assess temporal trends. Risk factors associated with seropositivity were determined by multivariable logistic regression. RESULTS: CMV seroprevalence in T1 of pregnancy was 23.4% (965/4111, 95% CI, 22.1-24.7%). The incidence rate for CMV primary infection during pregnancy was 1.8 (95% CI, 1.2-2.6) per 100 person-years. No changepoint was identified in the maternal CMV-seroprevalence trend. Multivariable analyses showed that T1 maternal CMV seropositivity was associated with having one child OR 1.3 (95% CI, 1.10-1.73) or two or more children OR 1.5 (95%CI, 1.1-2.1), ethnicity other than Caucasian OR 2.1 (95% CI, 1.1-3.8) and country of birth other than Canada and the USA OR 2.8 (95% CI, 1.5-4.9). CONCLUSIONS: In this cohort, maternal seroprevalence in T1 of pregnancy and seroconversion rate were low. This information and identified risk factors could help guide the development and implementation of preventive actions and evidence-based health policies to prevent CMV infection during pregnancy.
No takes yet. Share an insight, caveat, or question.
Balegamire et al. (2021) conducted a cohort in Pregnancy (Cytomegalovirus infection) (n=4,111). Country of birth other than Canada and the USA vs. Country of birth in Canada or the USA was evaluated on CMV seropositivity in the first trimester (OR 2.8, 95% CI 1.5-4.9, p=<0.001). First-trimester maternal CMV seroprevalence was 23.4%, with seropositivity significantly higher among women born outside Canada and the USA compared to those born in Canada or the USA (OR 2.8).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: